Arrowhead Pharmaceuticals (ARWR) Receivables (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 15 years of Receivables data on file, last reported at $15.7 million in Q1 2026.

• Quarterly Receivables rose 563.21% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (up 563.21% YoY) and the FY2025 annual result came in at $6.8 million, changed N/A from the prior year.
• Receivables slipped to $15.7 million in Q1 2026, from $228.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $228.2 million in Q4 2025 to a low of $239000.0 in Q2 2022.
• A 5-year average of $33.5 million and a median of $6.5 million in 2022 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 36278.67% in 2022, down 77.68% in 2022.
• Tracing ARWR's Receivables over 5 years: stood at $54.6 million in 2022, then tumbled by 94.43% to $3.0 million in 2023, then decreased by 17.74% to $2.5 million in 2024, then surged by 9027.24% to $228.2 million in 2025, then slumped by 93.13% to $15.7 million in 2026.
• The last three Receivables figures came in at $15.7 million (Q1 2026), $228.2 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.